Achilles Therapeutics Future Growth

Future criteria checks 0/6

Achilles Therapeutics's earnings are forecast to decline at 3.9% per annum. EPS is expected to decline by 1% per annum.

Key information

-3.9%

Earnings growth rate

-1.0%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated14 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:698 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-52-92N/A1
12/31/2025N/A-36-68N/A1
12/31/2024N/A-64-59N/A1
9/30/2024N/A-67-64-63N/A
6/30/2024N/A-64-49-48N/A
3/31/2024N/A-64-49-48N/A
12/31/2023N/A-70-50-48N/A
9/30/2023N/A-75-57-54N/A
6/30/2023N/A-71-63-58N/A
3/31/2023N/A-71-63-57N/A
12/31/2022N/A-71-67-60N/A
9/30/2022N/A-65-62-54N/A
6/30/2022N/A-66-67-60N/A
3/31/2022N/A-65-70-63N/A
12/31/2021N/A-61-67-59N/A
9/30/2021N/A-56-65-53N/A
6/30/2021N/A-51-66-51N/A
3/31/2021N/A-42-50-36N/A
12/31/2020N/A-33-37-25N/A
9/30/2020N/A-25-29-22N/A
6/30/2020N/A-19-21-19N/A
3/31/2020N/A-16-20-18N/A
12/31/2019N/A-14-15-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 698 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 698 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 698 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 698's revenue is forecast to grow faster than the German market.

High Growth Revenue: 698 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 698's Return on Equity is forecast to be high in 3 years time


Discover growth companies